The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • The Antibody Society’s Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

AIRR Community Meeting VI – That’s a Wrap!

June 25, 2022 by Pam Borghardt

The AIRR-C “raison d’etre” is the standardization of AIRR-seq data and its associated metadata, related software tools, pipelines and repositories, etc., as well as efforts aimed at other users, institutions, agencies, journals, and societies to promote international efforts to optimize FAIR practices: making data Findable, Accessible, Interoperable, and Reusable! Similarly, the spirit of accessibility of data, and training, equally applies to individuals from diverse backgrounds, including those from under-represented groups.  Using these premises as inspiration the sixth AIRR-C meeting theme “Exploring New Frontiers” was established.

The sixth AIRR Community Meeting (#AIRRC6) was held in La Jolla, CA from May 17-19, 2022.  The meeting had two themed “Challenge Sessions” meant to: (i) Initiate and implement a strategic plan for the AIRR Community that integrates the Working Groups’ activities toward the central goal of universally accepted AIRR-seq data standards; (ii) Introduce the Community to multidimensional systems approaches for characterizing immune responses, and how AIRR-seq data can benefit such approaches. 

Meetings and presentations took place at the Hilton La Jolla Torrey Pines as well as virtually. The meeting provided opportunities for investigators and trainees to network, to participate in AIRR Community Working Groups and Sub-committee meetings, to participate in poster sessions, to attend software tool demonstrations and tutorials, to participate in student mentoring sessions and matchups and to attend an industry networking reception with a “hot topics in the field” round table session.  We were delighted to have such an incredible turnout of industry collaborators and wish to extend our sincere thank you to our generous sponsors.

AIRR Community Meetings are the premier event for research on adaptive immune-receptor repertoires. They are also the primary location where the AIRR Community’s Working Groups and Sub-committees come together in one location to discuss how to push standardization in AIRR-sequencing (AIRR-seq) data and analysis forward.  For complete details about AIRR-C Meeting VI check out the final meeting booklet and the video recordings on the AIRR-C YouTube channel.

Just like the biology of immune repertoires is high-dimensional, this meeting’s success was as well!  We gathered some of the numbers that best describe the success of the AIRR-C VI meeting.

  • 4 Keynote speakers: Dennis Burton (Scripps Research), Gunilla Karlsson Hedestam (Karolinska Institutet),  Shane Crotty (La Jolla Institute for Immunology)  Atul Butte (University of California, San Francisco)
  • 144 in person attendees, 89 remote attendees, 20 countries represented
  • 13 Invited speakers, 6 contributed talks
  • 45 posters, 8 lightning demos, 6 deep dive tutorials
  • 5 hot topics in the field discussions
  • 19 sponsors – 5 gold, 5 silver, 7 bronze, 2 institutional 
  • 8 NIH travel award recipients

A big thank you again to our meeting sponsors for their generous sponsorship and engagement and to the AIRR-C Meetings Sub-committee members for their tireless effort in creating such an exceptional event.  

Looking forward to AIRR-C Meeting VII – rumour has it that it will be in Europe in Spring 2024!

Filed Under: Adaptive immune receptor repertoire, AIRR Community

Thanks to all who participated in Antibody Engineering & Therapeutics Europe!

June 9, 2022 by The Antibody Society

Another very successful Antibody Engineering & Therapeutics Europe has concluded!

The Antibody Society thanks all the volunteers who helped at the booth:

 

  • Demelza Willemsz (Genmab)
  • Thomas Wesselink (Genmab)
  • Chalana Zilvold – van den Oever (Genmab)
  • Charlotte Berendsen (Genmab)
  • Lisa King (Amsterdam UMC)
  • Milon de Jong (Amsterdam UMC)

In addition to Thomas, Milon and Lisa, Kerry Chester (Board of Directors member), Janine Schuurman (Society Vice President) and Sally Ward (Society President) appear in the image above.

We hope to see you in Amsterdam in June 2023 for the next Antibody Engineering & Therapeutics Europe.

Filed Under: Antibody Engineering & Therapeutics, The Antibody Society Tagged With: antibody engineering, antibody therapeutics

European Commission approves Lunsumio for people with relapsed or refractory follicular lymphoma

June 8, 2022 by The Antibody Society

On June 8, 2022, Roche announced that the European Commission granted conditional marketing authorization for Lunsumio® (mosunetuzumab), a T-cell engaging bispecific antibody that targets CD20 and CD3, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. Mosunetuzumab (RG7828, BTCT4465A) is an aglycosylated (N297G) humanized IgG1k bispecific antibody constructed using knobs-into-holes technology.

The approval is based on positive results from the Phase I/II GO29781 study (NCT02500407) in which Lunsumio demonstrated high complete response rates, with the majority of complete responders maintaining responses for at least 18 months, and favorable tolerability in people with heavily pre-treated FL. After a median follow-up of 18.3 months, the median duration of response among responders was 22.8 months (95% CI: 9.7-not estimable), the complete response rate was 60% (n=54/90), the objective response rate was 80% (n=72/90). Lunsumio is currently being evaluated in two Phase 3 studies: CELESTIMO, investigating Lunsumio plus lenalidomide in second line plus (2L+) FL, and SUNMO, investigating Lunsumio plus Polivy® (polatuzumab vedotin) in 2L+ diffuse large B-cell lymphoma.

Filed Under: Approvals Tagged With: approved antibodies, European Commission, mosunetuzumab

Join us on June 9th for our next webinar – Registration is open!

May 26, 2022 by The Antibody Society

In this webinar, Drs. Deane, Raybould and Boyles will share examples of how structure prediction enriches antibody sequence data and provide practical guidance for getting started using Oxford Protein Informatics Group (OPIG) tools to structurally featurise your antibody sequences. In particular, they will demonstrate the added value to tasks such as antibody functional clustering, repertoire disease-response diagnosis, and virtual screening.

Speaker bios are here.

Registration is open!

Filed Under: Adaptive immune receptor repertoire Tagged With: Adaptive Immune Receptor Repertoire Community

2022 Science Writing Competition winners announced!

May 15, 2022 by Janice Reichert

Congratulations to our winners!

To make science accessible, clear, concise communication is essential. The Antibody Society thus offers our student and post-doctoral fellow members a chance to grow this skill through a Science Writing Competition. Entrants submitted essays of 1200 – 1500 words on a topic related to antibody research that were evaluated by our panel of judges.

Our post-doc and student winners are:

Dr. Finn Wolfreys, University of California, San Francisco, CA, USA

Essay title: Antibody Discovery’s Diversity Problem

Alexander Brown, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Essay title: Immunity in a Deck of Cards

The winning essays can be accessed via the links above.

View all winning essays from the
Science Writing Competitions here

The  next Science Writing Competition opens in Feb. 2023.

Thanks to everyone who participated!

Filed Under: Antibody discovery, Competition, Immunology Tagged With: antibody discovery, Science Writing

« Previous Page
Next Page »

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • New episode of the On AIRR podcast is here! June 26, 2025
  • Zooming into the Community III — A Milestone Virtual Gathering! June 3, 2025
  • Register now for the June 26th AIRR Community Seminar Series June 3, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals